ACIU vs. PCRX, BLTE, KNSA, SYRE, MNKD, ANIP, AKRO, DAWN, MIRM, and ABCL
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Pacira BioSciences (PCRX), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Spyre Therapeutics (SYRE), MannKind (MNKD), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
AC Immune (NASDAQ:ACIU) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.
Pacira BioSciences received 556 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 71.81% of users gave Pacira BioSciences an outperform vote while only 62.25% of users gave AC Immune an outperform vote.
AC Immune currently has a consensus target price of $12.00, indicating a potential upside of 158.06%. Pacira BioSciences has a consensus target price of $47.40, indicating a potential upside of 56.28%. Given AC Immune's higher possible upside, equities analysts clearly believe AC Immune is more favorable than Pacira BioSciences.
AC Immune has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.
Pacira BioSciences has higher revenue and earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Pacira BioSciences has a net margin of 10.34% compared to AC Immune's net margin of 0.00%. Pacira BioSciences' return on equity of 12.98% beat AC Immune's return on equity.
In the previous week, Pacira BioSciences had 1 more articles in the media than AC Immune. MarketBeat recorded 8 mentions for Pacira BioSciences and 7 mentions for AC Immune. AC Immune's average media sentiment score of 0.93 beat Pacira BioSciences' score of -0.10 indicating that AC Immune is being referred to more favorably in the media.
51.4% of AC Immune shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 4.6% of AC Immune shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Pacira BioSciences beats AC Immune on 13 of the 17 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
